StreetAlpha.app
Home › Stocks › KYMR

Kymera Therapeutics, Inc. (KYMR)

Healthcare
$121.52
▼ −3.44%
LAST CLOSE · NOV 17

Kymera Therapeutics develops oral medicines for immune and inflammatory diseases using targeted protein degradation. It last closed at $121.52 on Nov 17, down 3.44% on the day. The average 12-month price target from 11 analysts is $148.00 (+21.8% from the last close), with a high of $170.00 and a low of $116.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in KYMR, 50% of them bullish and 50% bearish. In the past 30 days there were 4 dark pool prints totaling $2.4M, the largest $778K.

AI Auto Pilots
Is KYMR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$102.2M
+133.8% vs a year ago
Net income
−$349.4M
−341.8% margin
EPS (diluted)
−$3.64
Free cash flow
−$288.9M
−282.6% margin
Valuation
Market cap
$10.4B
85.4M shares
P/E
–
No P/E while losing money
Price to sales
101.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$373.4M
At Sep 30
Shareholder equity
$1.6B
Shares outstanding
85.4M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $72.8M$72.8MFY2021FY2022: $46.8M$46.8MFY2022FY2023: $78.6M$78.6MFY2023FY2024: $47.1M$47.1MFY2024FY2025: $39.2M$39.2MFY2025

From KYMR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 11 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
11firms
10 Buy1 Hold0 Sell
Each firm's latest rating on KYMR in the past 90 days
Average 12-month target
$148.00
▲ 21.8% upside

Based on 11 analysts who set a price target on KYMR in the past 90 days. The average target is $148.00, with a high of $170.00 and a low of $116.00, compared with the last close of $121.52.

Low $116.00Avg $148.00High $170.00
Blue marker: last close $121.52
Highest target$170.00
Average target$148.00
Lowest target$116.00
Latest rating changes
BarclaysTarget raised
Nov 2Buy$139 → $170
Truist SecuritiesTarget raised
Oct 30Buy$136 → $150
RBC CapitalTarget raised
Oct 30Hold$115 → $116
BTIGTarget raised
Oct 29Buy$134 → $139
Morgan StanleyMaintained
Oct 27Buy$146
DateFirmActionRatingPrice target
Nov 2BarclaysTarget raisedBuy$139 → $170
Oct 30Truist SecuritiesTarget raisedBuy$136 → $150
Oct 30RBC CapitalTarget raisedHold$115 → $116
Oct 29BTIGTarget raisedBuy$134 → $139
Oct 27Morgan StanleyMaintainedBuy$146
Loading…

Technical Analysis

KYMR · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 48). The nearest support is the Pivot S1 at $118.61, and the nearest resistance the Pivot at $122.23.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$142.4652 week high+17.2%
$125.13Pivot R1+3.0%
$125.0820 day average+2.9%
$123.00Swing high (Sep 23)+1.2%
$122.23Pivot+0.6%
$121.52Last close
$118.61Pivot S1−2.4%
$117.4050 day average−3.4%
$116.46Swing low (Aug 24)−4.2%
$115.81100 day average−4.7%
$99.94200 day average−17.8%
$62.9152 week low−48.2%
Indicators
RSI (14)47.80Middle of its rangeNeutral
MACD3.62Below its signal lineBearish
Stochastic35.9Middle of its rangeNeutral
ADX (14)29.8Trending up
Williams %R-83.3Oversold below −80, overbought above −20Oversold
CCI (20)-25.5Oversold below −100, overbought above 100Neutral
Rate of change−4.4%Change over 10 sessionsBearish
ATR (14)$6.57Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for KYMR

What happened before

See how KYMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KYMR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KYMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Nov 9 – Nov 16
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$2.4M
Largest print
$778K
Loading…

KYMR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲171 buying vs 112 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +24
  • ●Superinvestors: 1 added, 1 cut
  • ▼Put/call 1.53 to 1.66
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding302278+8.6%
In funds' top 101113−15.4%
Held by funds115.9%113.6%+2.2 pts
New / increased51 / 12046 / 97+19.6%
Reduced / sold out85 / 2783 / 26+2.8%
Put/call ratio1.661.53+8.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KYMR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYMR is in one of them and how their past KYMR trades turned out.

KYMR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KYMR in an article yet. Here's the latest on the wider market.

About Kymera Therapeutics

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that develops oral medicines. It uses targeted protein degradation, a method that taps into the body's own cell recycling system to remove proteins that cause disease. Its main focus is immunology, with programs aimed at conditions such as atopic dermatitis and asthma, which are often treated with injections. Its medicines are still in clinical testing and are intended for patients with these conditions.

Headquarters
Watertown, MA